|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:sodium_oxybate
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N07XX04
|
|
gptkbp:chemicalClass
|
oxybates
|
|
gptkbp:contraindication
|
concurrent use with sedative hypnotics
succinic semialdehyde dehydrogenase deficiency
|
|
gptkbp:form
|
oral solution
|
|
gptkbp:halfLife
|
0.5 to 1 hour
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xyrem
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_controlled_substance_(US)
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Jazz_Pharmaceuticals
|
|
gptkbp:otherName
|
gptkb:sodium_oxybate
gamma-hydroxybutyric acid sodium salt
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
respiratory depression
potential for abuse
CNS depression
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
confusion
nausea
dizziness
headache
enuresis
|
|
gptkbp:usedFor
|
narcolepsy
excessive daytime sleepiness
cataplexy
|
|
gptkbp:bfsParent
|
gptkb:Jazz_Pharmaceuticals
gptkb:Sodium_oxybate
gptkb:GHB
gptkb:Orphan_Medical,_Inc.
|
|
gptkbp:bfsLayer
|
7
|